Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602821 | 0.92 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL27718339 | 0.91 | ALOX15 (0.63) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL9373986 | 0.90 | ALOX15 (0.57) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL4645271 | 0.90 | ALOX15 (0.57) | ALOX15KMT2AMEN1ALPLALPI | |
| Acetonitrile SCHEMBL23706321 | 0.89 | ALOX15 (0.55) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL8343122 | 0.89 | L3MBTL1 (0.60) | ALOX15KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL264347 | 0.88 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL2723659 | 0.88 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL4645756 | 0.88 | ALOX15 (0.59) | ALOX15KMT2AMEN1ALPLALPI | |
| SCHEMBL4644546 | 0.87 | ALOX15 (0.53) | ALOX15KMT2AMEN1ALPLALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725949-A1 | IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES | BioSpring Gesellschaft für Biotechnologie mbH (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4725950-A1 | IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES | BioSpring Gesellschaft für Biotechnologie mbH (DE) | 2026-04-15 | — | — | EP | claimed |
| US-20260097383-A1 | SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES | BioSpring Gesellschaft für Biotechnologie mbH (DE) | 2026-04-09 | — | — | US | claimed |
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12454613-B2 | Biodegradable resin and film prepared thereby | TORAY INDUSTRIES, INC. (JP) | 2025-10-28 | — | — | US | claimed |
| CN-119461336-A | Modification method of fluorocarbon, modified fluorocarbon and lithium/fluorocarbon battery | 惠州亿纬锂能股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119390744-A | Method for improving purity of long-chain nucleic acid synthesized by solid-phase phosphoramidite triester method and application thereof | 江苏汉凰科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119340484-A | Electrolyte and fluorocarbon battery | 惠州亿纬锂能股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119008954-A | Additive for positive electrode slurry of lithium ion battery, positive electrode slurry, positive electrode plate and lithium ion battery | 广东金晟新能源股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | claimed |
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | claimed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | claimed |
| US-20090306400-A1 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. | HENRI JOHN T | 2009-12-10 | — | — | US | claimed |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-05-28 | — | — | US | claimed |
| EP-2017282-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2009-01-21 | — | — | EP | claimed |
| EP-2007739-A2 | A CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES | Tapestry Pharmaceuticals, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007126893-A2 | A CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES | TAPESTRY PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070225510-A1 | Convergent Process for the Synthesis of Taxane Derivatives | TAPESTRY PHARMACEUTICALS, INC. | 2007-09-27 | — | — | US | claimed |
| EP-0077029-B1 | RENIN INHIBITORY PEPTIDES | MERCK & CO. INC. (US) | 1985-08-21 | — | — | EP | claimed |
| EP-0077029-A2 | Renin inhibitory peptides | MERCK & CO. INC. (US) | 1983-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097383-A1 | SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES | RNGTT, NSUN2, RNMT | ALOX15 1691/4885KMT2A 2129/4885MEN1 4716/4885 |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | RNGTT, DUT, ADAR | ALOX15 1412/4885KMT2A 361/4885MEN1 3961/4885 |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, HABP2, DPP9 | ALOX15 2674/4885KMT2A 3948/4885MEN1 1744/4885 |
| US-20070225510-A1 | Convergent Process for the Synthesis of Taxane Derivatives | DHPS, TSN, EIF5B | ALOX15 3351/4885KMT2A 4296/4885MEN1 665/4885 |
| US-20090306400-A1 | CONVERGENT PROCESS FOR THE SYNTHESIS OF TAXANE DERIVATIVES. | DHPS, TSN, PARP15 | ALOX15 3598/4885KMT2A 4288/4885MEN1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.